Program Management

Stefan Ståhl

Stefan Ståhl received his PhD 1992, and became professor 1999. Between 2006 and 2013 he was the Dean for the School of Biotechnology, KTH. Professor Ståhl has filed a number of patents, and is the cofounded of several biotech companies, in addition he has published more than 185 scientific papers in international peer-reviewed journals (h-index 52, >9300 citations), supervised 20 PhD students to their dissertation and given over 75 lectures as invited speaker at various international meetings and conferences. His research has focused on affinity proteins, denoted affibody ligands, and to explore their potential in various therapeutic settings, including tumor targeting for medical imaging and radiotherapy applications.

Professor Ståhl is the program group leader for Next Generation Antibody Therapeutics program.

John Löfblom

John Löfblom is an Associate Professor since 2015 at the Division of Protein Technology at KTH and an expert on protein engineering technology. He received his PhD in 2008 and became Assistant Professor as part of a new tenure track program at KTH in 2011. Dr. Löfblom has published more than 40 peer-reviewed papers, filed more than eight patents, supervised three PhD students to dissertation and given over 15 invited lectures at international conferences. Within the WCPR project, his group is developing  new protein-based drugs for targeting of angiogenesis with an initial focus on VEGFR2 that is a key receptor in progression of several different cancers as well as ophthalmic diseases. The main goal is to further develop and explore biparatopic antagonistic ligands for VEGFR2 with an unusual mechanism of binding to two distinct sites on the receptor (like a paper staple), resulting in pM affinity.

Dr Löfblom is principal investigator for the Next generation antibody therapeutics project.